German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (<scp>SCENESSE</scp>) in Patients With Erythropoietic Protoporphyria (<scp>EPP</scp>)
Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients. The study shows a positive safety profile of afamelanotide, with the treatment providing an ongoing clinical benefit.
Authors
- D. Bruch‐Gerharz
- C Schlegel
- Pilar Bilbao
- Joanna Wegner (ORCID: https://orcid.org/0000-0002-7710-9675)
- Petra Staubach (ORCID: https://orcid.org/0000-0002-2276-0284)
- Lea Kiefer (ORCID: https://orcid.org/0000-0003-2882-4784)
- Bernhard Homey (ORCID: https://orcid.org/0000-0002-5784-4146)
- Karsten Weller (ORCID: https://orcid.org/0000-0003-4437-0313)
- Kathrin Schelonke
- Gillian C. Walker
- Ulrich Stölzel
- Regine Keller‐Melchior
- Malgorzata Bochno
Institutions
- Johannes Gutenberg University Mainz (DE)
- Humboldt-Universität zu Berlin (DE)
- Düsseldorf University Hospital (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Klinikum Chemnitz (DE)
- Heinrich Heine University Düsseldorf (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Photodermatology Photoimmunology & Photomedicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/phpp.13012
- Citations
- 3
- Primary Topic
- Porphyrin Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.42